James Peyer, Director, 10% Owner at Sensei Biotherapeutics, Inc. (SNSE), bought 94,820 shares at $4.94 ($457K) on 2022-01-21, disclosed to the SEC on 2022-01-25.
Open-market purchase of $457k SNSE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.94 | 24,703 | $122K | 26.7% |
| 2 | $4.94 | 24,703 | $122K | 26.7% |
| 3 | $4.69 | 22,707 | $106K | 23.3% |
| 4 | $4.69 | 22,707 | $106K | 23.3% |
| Total | $4.82 avg | 94,820 | $457K | 100% |
| Filing → |
| SNSE | SELL | 2025-12-08 | $398K | — | Filing → |
| SNSE | BUY | 2022-04-21 | $15K | — | Filing → |
| SNSE | BUY | 2022-04-21 | $136K | — | Filing → |